Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-25

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypertension is known to be the major risk factor for stroke. The most common cause of secondary hypertension, primary aldosteronism (PA), is characterized by the excessive secretion of aldosterone and is related to hypertension and hypokalemia. PA accounts for 3-10 % of hypertensive patients, and a higher incidence of vascular complications compared to patients with essential hypertension was observed in several studies. The vascular injury from excessive aldosterone can occur via oxidative stress and collagen remodeling, causing endothelial dysfunction and fibrosis in the vasculature.

The association between cerebral small vessel disease (cSVD) and hypertension has been well studies in the past decades. However, not much study has focused on the cSVD burden in patient with PA. The goal of this study is to understand the features of cSVD in patients with PA and for the purpose of understanding the underlying pathophysiology of cerebrovascular injury in this particular patient group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Screening for Primary Aldosteronism in a Population of Patients With Hypertension

NCT03105531

Primary Aldosteronism Hypertension Hypertension Secondary

COMPLETED

Prospective Study on Primary Aldosteronism in Resistant Hypertension

NCT04213963

Resistant Hypertension Primary Aldosteronism Refractory Hypertension +3 more

RECRUITING

Primary Hyperaldosteronism and Ischemia-reperfusion Injury

NCT01978132

Primary Hyperaldosteronism

COMPLETED NA

Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China

NCT01459042

Hypertension, Resistant to Conventional Therapy

COMPLETED

Chongqing Primary Aldosteronism Study

NCT03224312

Primary Aldosteronism

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with primary aldosteronism

Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.

Group Type EXPERIMENTAL

Brain MRI

Intervention Type DIAGNOSTIC_TEST

Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.

Patient with essential hypertension

Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.

Group Type ACTIVE_COMPARATOR

Brain MRI

Intervention Type DIAGNOSTIC_TEST

Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brain MRI

Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 20-90 years-old
* patient with primary aldosteronism or healthy control
* consciousness clear
* willing to receive brain MRI

Exclusion Criteria

* renal failure or Creatinine \> 2mg/dl
* coagulopathy or hepatic insufficiency
* unstable vital sign under inotropic agents
* pregnancy
* metal implant or cardiac pacemaker
* major brain surgery

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes